Drugs / ANPOCOGIN

Trials 6 · a red edge is where a trial was stopped

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT07333820 Feb → Jul 2026 overdue gastric cancer Yonsei University Not yet recruiting No outcome recorded
Phase 1 NCT06341647 Oct 2024 → Apr 2027 breast cancer, gastric cancer, gastroesophageal junction adenocarcinoma GC Cell Corporation Withdrawn No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT05678205 Aug 2023 → Apr 2027 breast cancer, gastric cancer, gastroesophageal junction adenocarcinoma Artiva Biotherapeutics, Inc. Withdrawn No outcome recorded
Phase 1/2 NCT00443573 Dec 2006 → Aug 2007 colon carcinoma ARCA Biopharma, Inc. Suspended No outcome recorded
Phase 21 trial
Phase 2 NCT00116012 Jun 2005 → ? coronary artery disorder ARCA Biopharma, Inc. Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT04655586 Dec 2020 → Dec 2021 COVID-19 ARCA Biopharma, Inc. Completed No outcome recorded

Evidence & citations 13 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as ANPOCOGIN ChEMBL registry synonym — accepted as the source's own label CHEMBL4298082
Known as AB-201 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07333820
2

NCT05678205

NCT06341647

Known as Anpocogina ChEMBL registry synonym — accepted as the source's own label CHEMBL4298082
Known as Anpocogine ChEMBL registry synonym — accepted as the source's own label CHEMBL4298082
Known as Nematode anticoagulant protein c2 ChEMBL registry synonym — accepted as the source's own label CHEMBL4298082
Known as Recombinant NAPc2 Recombinant NAPc2 is a potent inhibitor of the tissue factor/factor VIIa complex that has the potential to reduce ischemic complications mediated by thrombin generation.” PMID 17599602 Jun 2007
Known as Recombinant nematode anticoagulant protein c2 “OBJECTIVES: We sought to evaluate the safety and efficacy of recombinant nematode anticoagulant protein c2 (rNAPc2) in patients with non-ST-segment elevation acute coronary...” PMID 17599602 Jun 2007
1

recombinant nematode anticoagulant protein c2 (rNAPc2)” NCT00443573

Known as Recombinant nematode anticoagulant protein c2 (rnapc2) ChEMBL registry synonym — accepted as the source's own label CHEMBL4298082
Known as rNAPc2 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04655586
2

NCT00116012

NCT00443573

Action Inhibit “Recombinant NAPc2 is a potent inhibitor of the tissue factor/factor VIIa complex” PMID 17599602 Jun 2007
Modality Protein / enzyme biologic “Recombinant nematode anticoagulant protein c2 (rNAPc2)” NCT00116012
Route Intravenous “double-blinded intravenous rNAPc2 or placebo every 48 h” PMID 17599602 Jun 2007
Target TF “novel TF inhibitor rNAPc2” PMID 37381988 Jun 2023